Table 2.
Hazard ratios of baseline characteristics for all-cause mortality in gastric cancer patients (univariate and multivariate analyses)
| Univariate analysis HR (95% CI) | p-value | Multivariate analysis HR (95% CI) | p-value | |
|---|---|---|---|---|
| Patient-related factors | ||||
| Sex (male/female) | 1.019 (0.825–1.257) | 0.863 | ||
| Age (years) (<65/≥65) | 1.514 (1.234–1.857) | <0.01 | 1.604 (1.289–1.997) | <0.01 |
| COC-NLR (ref: low) | <0.01 | <0.01 | ||
| Medium | 1.863 (1.403–2.474) | 1.693 (1.195–2.397) | <0.01 | |
| High | 4.223 (3.382–5.271) | 2.698 (1.504–4.841) | <0.01 | |
| Neutrophils (×109/L)(<3.61/≥3.61) | 2.075 (1.684–2.558) | <0.01 | 1.371 (1.052–1.785) | 0.02 |
| Lymphocytes (×109/L)(<3.56/≥3.56) | 0.927 (0.414–2.077) | 0.855 | ||
| Platelet (×109/L)(<315.5/≥315.50) | 1.422 (1.117–1.810) | 0.004 | 1.105 (0.822–1.485) | 0.51 |
| CRP (mg/L) (<4.29/≥4.29) | 3.265 (2.676–3.983) | <0.01 | 1.149 (0.607–2.176) | <0.01 |
| Albumin (g/L) (<48.45/≥48.45) | 1.459 (0.821–2.592) | 0.198 | ||
| AGR (<2.5/≥2.5) | 0.210 (0.169–0.262) | <0.01 | 2.847 (1.331–6.091) | <0.01 |
| NLR (<2.5/≥2.5) | 0.210 (0.169–0.262) | <0.01 | 1.345 (0.965–1.875) | 0.08 |
| PLR (<125.31/≥125.31) | 1.443 (1.181–1.763) | <0.01 | 1.105 (0.822–1.485) | 0.51 |
| SII (<521.56/≥521.56) | 1.762 (1.444–2.151) | <0.01 | 0.795 (0.573–1.103) | 0.17 |
| GPS (ref: 0) | <0.01 | 0.21 | ||
| 1 | 2.297 (1.808–2.919) | <0.01 | 0.868 (0.618–1.219) | 0.42 |
| 2 | 3.689 (2.551–5.336) | <0.01 | 0.443 (0.179–1.097) | 0.08 |
| mGPS (ref: 0) | <0.01 | 0.14 | ||
| 1 | 0.312 (0.235–0.414) | <0.01 | 1.052 (0.709–1.559) | 0.80 |
| 2 | 0.762 (0.569–1.020) | 0.068 | 0.689 (0.386–1.229) | 0.21 |
| HS-mGPS (ref: 0) | <0.01 | 0.02 | ||
| 1 | 2.579 (2.091–3.181) | <0.01 | 0.987 (0.668–1.459) | 0.74 |
| 2 | 4.124 (2.944–5.775) | <0.01 | 2.764 (1.242–6.150) | 0.06 |
| CRP/Alb ratio (<0.096/≥0.096) | 2.945 (2.076–4.179) | <0.01 | 1.501 (0.910–2.477) | 0.11 |
| Tumor-related factors | ||||
| Tumor location (ref: lower) | <0.01 | <0.01 | ||
| Middle | 1.412 (1.051–1.895) | 0.022 | 1.312 (0.970–1.776) | 0.08 |
| Upper | 2.453 (1.946–3.092) | <0.01 | 1.813 (1.417–2.319) | <0.01 |
| Tumor size (cm) (<2.9/≥2.9) | 3.051 (2.207–4.217) | <0.01 | 0.933 (0.651–1.338) | 0.71 |
| Histological type (ref: poor-differentiated adenocarcinoma) | 1.365 (1.104–1.687) | <0.01 | 0.718 (0.575–0.897) | <0.01 |
| Metastatic lymph node ratio (<0.18/≥0.18) | 4.753 (3.817–5.919) | <0.01 | 2.099 (1.526–2.888) | <0.01 |
| TNM stage (ref: IA) | <0.01 | <0.01 | ||
| IB | 0.037 (0.015–0.091) | <0.01 | 1.625 (0.513–5.147) | 0.41 |
| IIA | 0.072 (0.034–0.153) | <0.01 | 3.153 (1.094–9.089) | 0.03 |
| IIB | 0.129 (0.072–0.231) | <0.01 | 4.765 (1.833–12.389) | 0.01 |
| IIIA | 0.235 (0.167–0.331) | <0.01 | 5.992 (2.286–15.710) | <0.01 |
| IIIB | 0.377 (0.269–0.527) | <0.01 | 7.352 (2.807–19.254) | <0.01 |
| IIIC | 0.631 (0.497–0.802) | <0.01 | 9.639 (3.620–25.669) | <0.01 |
Note: Bold figures represent as statistically significant, p<0.05.
Abbreviations: NLR, neutrophil to lymphocyte ratio; CRP, C-reactive protein; COC-NLR, combination of CRP and NLR; AGR, albumin globulin ratio; GPS, Glasgow Prognostic Score; mGPS, modified Glasgow Prognostic Score; HS-mGPS, high-sensitivity modified Glasgow Prognostic Score; TNM, tumor-node-metastasis; Alb, albumin; PLR, platelet to lymphocyte ratio; SII, systemic immune inflammation index; HR, hazard ratio; Ref, reference.